Australian public assessment report for denosumab

Treatment with denosumab is associated with a marked reduction in markers of bone resorption such as uNTX and serum C-telopeptide (sCTX) (20040215) and a notable reduction in metabolic activity in the tumour as assessed by fludeoxyglucose (18F) positron emission tomography (18FDG-PET) scan (integrated analysis). ................
................